Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Go back to Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease| (NYSE: BHVN) | Delayed: 13.62 -0.27 (1.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.89 | 52 Week High | $ | |||
| Open | $14.07 | 52 Week Low | $ | |||
| Day High | $14.37 | P/E | N/A | |||
| Day Low | $13.46 | EPS | $ | |||
| Volume | 6,431,852 | |||||
